David Pariser, James Spencer, Brian Berman, Suzanne Bruce, Lisa Parr, Kenneth Gross
Department of Dermatology, Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, Virginia.
J Clin Aesthet Dermatol. 2009 May;2(5):38-43.
To evaluate the efficacy and tolerability of using a 4% hydroquinone/0.05% tretinoin skin care system compared with standard treatment of cleanser plus healing ointment to enhance aesthetic outcomes resulting from electrodesiccation and curettage treatment for superficial truncal basal cell carcinomas.
Multicenter, investigator-masked, randomized, parallel-group study. Patients received either the hydroquinone/tretinoin system or the standard treatment twice daily for three weeks before and after electrodesiccation and curettage (postelectrodesiccation and curettage, lesions received standard treatment until reepithelialization was >75 percent; assigned treatment regimens then resumed).
Patients attending academic, institutional, and private dermatology clinics.
51 patients with 1 to 3 superficial truncal basal cell carcinomas.
The primary efficacy outcome was the incidence of treatment success for scar cosmesis, defined as a global assessment of excellent or good wound appearance (on a scale of excellent, good, fair, and poor), as evaluated by the investigators. After the end of the study, seven expert masked graders (dermatologists or plastic surgeons) reviewed the photographs from all of the lesions and also evaluated global assessment.
The incidence of treatment success in the hydroquinone/tretinoin and standard treatment groups was 72 percent versus 63 percent according to the masked investigators and 45 to 68 percent versus 20 to 44 percent, respectively, according to the seven expert masked graders. All the expert graders reported a higher incidence of treatment success with the hydroquinone/ tretinoin system than with standard treatment and this difference was statistically significant for five of the seven graders.
The adjunctive use of the hydroquinone/tretinoin skin care system may offer enhanced aesthetic results postelectrodesiccation and curettage compared with standard treatment. (J Clin Aesthetic Dermatol. 2009;2(5):38-43.).
评估4%氢醌/0.05%维甲酸皮肤护理系统与标准治疗(洁面乳加愈合软膏)相比,在改善躯干浅表基底细胞癌电干燥刮除术后美学效果方面的疗效和耐受性。
多中心、研究者设盲、随机、平行组研究。患者在电干燥刮除术前及术后3周,每天两次接受氢醌/维甲酸系统治疗或标准治疗。(电干燥刮除术后,病变部位接受标准治疗直至上皮再形成超过75%;之后恢复分配的治疗方案)。
在学术、机构和私立皮肤科诊所就诊的患者。
51例患有1至3个躯干浅表基底细胞癌的患者。
主要疗效指标为瘢痕美容治疗成功的发生率,定义为研究者评估的整体伤口外观为优或良(分为优、良、中、差)。研究结束后,7名设盲专家评分员(皮肤科医生或整形外科医生)查看了所有病变的照片,并进行了整体评估。
根据设盲研究者评估,氢醌/维甲酸组和标准治疗组的治疗成功发生率分别为72%和63%;根据7名设盲专家评分员评估,分别为45%至68%和20%至44%。所有专家评分员均报告氢醌/维甲酸系统治疗成功的发生率高于标准治疗,7名评分员中有5名差异具有统计学意义。
与标准治疗相比,氢醌/维甲酸皮肤护理系统辅助使用可能会改善电干燥刮除术后的美学效果。(《临床美容皮肤科杂志》。2009年;2(5):38 - 43。)